



## Evofem Biosciences to Present at Aegis Virtual Conference on Wednesday, February 23, 2022

SAN DIEGO, Feb. 8, 2022 /PRNewswire/ -- Evofem Biosciences, Inc., (NASDAQ: EVFM) will present at the Aegis Virtual Conference as follows:

---

Date: Wednesday, February 23, 2022

Time: 4:30 p.m. ET (1:30 p.m. PT)

Access Webcast: <https://evofem.investorroom.com/Aegis2022> or  
<https://us02web.zoom.us/j/86168915443>

Add to Calendar: [iCalendar \(.ics\) file](#)

### About Evofem Biosciences

Evofem Biosciences, Inc., (NASDAQ: EVFM) is developing and commercializing innovative products to address unmet needs in women's sexual and reproductive health, including hormone-free, woman-controlled contraception and protection from certain sexually transmitted infections (chlamydia and gonorrhea). The Company's first FDA-approved product, Phexxi® (lactic acid, citric acid and potassium bitartrate), is a hormone-free, on-demand prescription contraceptive vaginal gel. It comes in a box of 12 pre-filled applicators and is applied 0-60 minutes before each act of sex. Learn more at [phexxi.com](http://phexxi.com) and [evofem.com](http://evofem.com).

Phexxi® is a registered trademark of Evofem Biosciences, Inc.

### Investor Relations Contact

Amy Raskopf

Evoform Biosciences, Inc.

[araskopf@evofem.com](mailto:araskopf@evofem.com)

Mobile: (917) 673-5775

SOURCE Evoform Biosciences, Inc.